Neuropathic Pain Therapeutics Summit
Start Date: 2021-08-24
End Date: 2021-08-25
Time: 8:00 am to 5:00 pm
The First Industry-Dedicated Conference Focused on Accelerating Novel Neuropathic Pain Therapeutics into the Clinic.
The opioid crisis rages on unabated. Meanwhile, the global population continues to age, creating an enormous need for next-generation neuropathic pain treatment and management approaches. This has stimulated a renewed sense of urgency to discover, translate and accelerate non-addictive and clinically effective pain relief therapeutics into the clinic and to patients in pain.
As such, the Neuropathic Pain Therapeutics Digital Summit arrives as the first-ever industry dedicated meeting for large pharma, biotech and academia, to discover novel, non-addictive neuropathic pain therapeutic mechanisms of action.
Expect to be involved in interactive discussions on the diversity of next-generation neuropathic pain drugs in development including NaV1.7 channel inhibitors, antisense oligonucleotides, matrix metalloproteinase inhibitors, gene therapy, anti-TRPV1 antibody, cannabinoid-derived pharmaceutical, neuroimmune targeted, medical device approaches, and more!
This is your chance to understand the latest findings on the underlying pathophysiology of neuropathic pain. Overcome preclinical model challenges to identify pain biomarkers and harness the neuroimmune axis to tackle neuropathic pain and discuss novel pharmacological approaches along the neuropathic pain patient continuum of care.
The time is now to shape the future fabric of neuropathic pain drug development and to make a meaningful dent on the opioid crisis. Make sure to be part of this unique forum to strengthen your pipeline of neuropathic pain therapeutics and accelerate them into the clinic and to patients in need.
Group discounts and early booking rates are available. Please visit the website for full pricing information www.neuropathic-pain-therapeutics.com
Speakers: Steven Fox, Chairman and Founder, Akelos, Inc, Irving Sucholeiki, President and Chief Executive Officer, Aquilus Pharmaceuticals, Gary J. Bennett, Co-Founder, BioIntervene Inc., Richard Malamut, Chief Medical Officer and EVP, Collegium Pharmaceuticals, Lizandra Marcondes, Head of Medical Affairs US, Grunenthal/ Averitas, Patrick Sheets, Associate Professor of Pharmacology and Toxicity, Indiana University School of Medicine, Peter McNaughton, Professor of Pharmacology, King’s College London, Darrell A. Henze, Director – Neuroscience, Merck and Co., Inc., Fernando Aleman, Co-Founder and Chief Scientific Officer, Navega Therapeutics, Douglas E. Brenneman, Director of Pharmacology, Neuropathix, Inc., Joseph Foss, Chief Medical Officer, NeuroTherapia, Eric Grigsby, President and Chief Executive Officer, Neurovations, Smriti Iyengar, Director – Preclinical Screening Platform for Pain and Program Director, National Institute on Neurological Disorders and Stroke/ NIH, Daniela Papadia, Head of Discovery and Preclinical R and D – Ion Channel Targets in Pain, Oblique Therapeutics, Owen McManus, Chief Technology Officer, Q-State Biosciences, David Michelson, Chief Medical Officer, Regenacy Pharmaceuticals, Daniela Salvemini, Professor, St. Louis University School of Medicine, Sara Jane Ward, Assistant Professor of Pharmacology, Temple University Lewis Katz School of Medicine, Aurelia de Pauw, Sr Vice President, Clinical Programs / Medical Affairs, Tetra Bio-Pharma, Selwyn Jayakar, Instructor in Neurology, Woolf Lab, Boston Children’s Hospital, Stephen D. Collins, Chief Medical Officer, Xalud Therapeutics
Conference - Industry - Early Bird Available: USD 1199.00,
Conference - Academic - Early Bird Available: USD 899.00
Click the link for registration or ticketing information:
Organized by : Hanson Wade Tel : (+1) 617 455 4188